LABORATORY CORP OF AMERICA HOLDINGS
10-K405/A, 1998-04-29
MEDICAL LABORATORIES
Previous: GUARANTY FINANCIAL CORP /VA/, 424B1, 1998-04-29
Next: FIRST VIRTUAL CORP, S-1/A, 1998-04-29



10K405/A-The Company's Annual Report on Form 10-K for the year ended December
31, 1997 dated March 30, 1998 and filed with the Commissionon March 30, 1998
(the "1997 Form 10-K") is hereby amended as set forth herein.

               UNITED STATES SECURITIES AND EXCHANGE COMMISSION
                            WASHINGTON, D.C.  20549
                                   FORM 10-K/A
(Mark One)
          ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
- -----
     EXCHANGE ACT OF 1934
For the fiscal year ended       DECEMBER 31, 1997
                          ----------------------------------------------------
                                      OR
        TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
- -----
        SECURITIES EXCHANGE ACT OF 1934

For the transition period from                         to
                                    ------------------    ----------------
Commission file number                   1-11353
                      --------------------------------------------------------
                  LABORATORY CORPORATION OF AMERICA HOLDINGS
- ------------------------------------------------------------------------------
            (Exact name of registrant as specified in its charter)
                                       
         DELAWARE                               13-3757370
- ------------------------------------------------------------------------------
(State or other jurisdiction of             (I.R.S. Employer
 incorporation or organization)             Identification No.)

  358 SOUTH MAIN STREET, BURLINGTON, NORTH CAROLINA            27215
- -------------------------------------------------------------------------------
     (Address of principal executive offices)               (Zip Code)

                        336-229-1127
- ------------------------------------------------------------------------------
     (Registrant's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

   Title of each class                     Name of exchange on which registered
- --------------------------                 ------------------------------------
Common Stock, $0.01 par value              New York Stock Exchange
Common Stock Purchase Warrants             New York Stock Exchange
Redeemable Preferred Stock,$.10 par value  New York Stock Exchange

Securities registered pursuant to Section 12(g)of the Act: None

Indicate  by  check  mark whether the registrant (1)  has  filed  all  reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act  of
1934  during  the  preceding 12 months (or for such shorter  period  that  the
registrant was required to file such reports) and (2) has been subject to such
filing requirements for the past 90 days.  Yes  X  No
                                               ---    ---

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405
of  Regulation S-K is not contained herein, and will not be contained, to  the
best  of registrant's knowledge, in definitive proxy or information statements
incorporated  by reference in Part III of this Form 10-K or any  amendment  to
this Form 10-K.  X
               -----

State the aggregate market value of the voting stock held by non-affiliates of
the registrant, by reference to the price at which the stock was sold as of  a
specified  date  within 60 days prior to the date of filing:  $126,340,062  at
March 13, 1998.

Indicate the number of shares outstanding of each of the registrant's  classes
of  common  stock,  as of the latest practicable date: 124,499,287  shares  at
March  13, 1998, of which 61,329,256 shares are held by indirect wholly  owned
subsidiaries  of  Roche  Holdings Ltd. The number of warrants  outstanding  to
purchase  shares of the issuer's common stock is 22,151,308 as  of  March  13,
1998,  of  which 8,325,000 are held by an indirect wholly owned subsidiary  of
Roche Holdings Ltd.

The Company's Annual Report on Form 10-K for the year ended  December 31, 1997
dated March 30,  1998 and filed  with  the  commission on March 30,  1998 (the
"1997 Form 10-K" is hereby amended as set forth herein.

                                   PART III

      The  information required by Part III, Items 10 through 13, of Form 10-K
is  incorporated by reference from the registrant's definitive proxy statement
for its 1998 annual meeting of stockholders, which is to be filed pursuant  to
Regulation 14A not later than April 30, 1998.
<PAGE>
<PAGE>
                                  SIGNATURES


Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange
Act  of  1934,  the Company has duly caused this report to be  signed  on  its
behalf by the undersigned, thereunto duly authorized.

                           LABORATORY CORPORATION OF AMERICA HOLDINGS
                           ------------------------------------------
                                        Registrant


                              By:/s/ THOMAS P. MAC MAHON
                                 ------------------------------------
                                 Thomas P. Mac Mahon
                                 Chairman of the Board, President
                                 and Chief Executive Officer






Dated:  April 29, 1998
<PAGE>
<PAGE>

     Pursuant to the requirements of the Securities Exchange Act of 1934, this
report  has  been  signed by the following persons on April 29,  1998  in  the
capacities indicated.

     Signature                          Title
     ---------                          -----



/s/ THOMAS P. MAC MAHON                 Chairman of the Board, 
- --------------------------------------  President and Chief
Thomas P. Mac Mahon                     Executive Officer
                                        (Principal Executive Officer)

/s/ WESLEY R. ELINGBURG                 Executive Vice President,   
- --------------------------------------  Chief Financial Officer
Wesley R.Elingburg                      and Treasurer
                                        (Principal Financial Officer and
                                        Principal Accounting Officer)

/s/ JEAN-LUC BELINGARD*                 Director
- --------------------------------------
Jean-Luc Belingard

/s/ WENDY E. LANE*                      Director
- --------------------------------------
Wendy E. Lane

/s/ ROBERT E. MITTELSTAEDT, JR.*        Director
- --------------------------------------
Robert E. Mittelstaedt, Jr.

/s/ JAMES B. POWELL, M.D.*              Director
- --------------------------------------
James B. Powell, M.D.

/s/ DAVID B. SKINNER, M.D.*             Director
- --------------------------------------
David B. Skinner, M.D.

/s/ ANDREW G. WALLACE, M.D.*            Director
- --------------------------------------
Andrew G. Wallace, M.D.

- -----------------------------------

*   Bradford T. Smith, by his signing his name hereto, does hereby  sign  this
report  on  behalf of the directors of the Registrant after whose typed  names
asterisks  appear,  pursuant  to  powers of attorney  duly  executed  by  such
directors and filed with the Securities and Exchange Commission.

By:/s/ BRADFORD T. SMITH
   --------------------------------------
   Bradford T. Smith
   Attorney-in-fact




© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission